UroGen Pharma Ltd (URGN)
Healthcare
Biotechnology
38.20 $
-6.9%
vs. previous close
Closing price · As of: 31. Jul 2026
UroGen Pharma Ltd (URGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -45 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20 | -17 | -13 | -32 | -24 | -28 | -14 | -42 | -40 | -42 | -38 | -45 | -166 | |
| 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.5 | 0.6 | 0.6 | 0.7 | 0.7 | 2.6 | |
| 2.2 | 2.2 | 2.6 | 2.8 | 3.6 | 3.5 | 3.3 | 3.1 | 2.7 | 3.0 | 3.1 | 4.6 | 14 | |
| 2.2 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -1.9 | -1.1 | 6.6 | -4.0 | 2.6 | -9.1 | 15 | -2.6 | 5.2 | -14 | -18 | -30 | -57 | |
| 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.3 | |
| 3.7 | 0.4 | -11 | 14 | 12 | -107 | 61 | -26 | 28 | 31 | 28 | -21 | 67 | |
| 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | 0.0 | 0.0 | – | – | -1.9 | 65 | – | |
| 0.1 | 116 | 0.0 | 55 | 100 | 40 | 0.1 | 0.0 | 0.3 | 8.3 | 31 | 65 | 105 | |
| -16 | 99 | -24 | 36 | 89 | -95 | 47 | -68 | -11 | -2.6 | 21 | -0.8 | 6.2 | |
| -20 | -17 | -13 | -32 | -24 | -28 | -14 | -42 | -40 | -42 | -38 | -45 | -166 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.